RVMD Stock Rises on Detailed Results From Pancreatic Cancer Study
Revolution Medicines jumps after detailed phase III data show daraxonrasib cuts death risk by 60% and doubles median survival in treated pancreatic cancer.
Zacks
Nasdaq, S&P 500 Futures Open June On Strong Footing: Why NVDA, DELL, HPE, TSM, TSLA, SPCE, RVMD Are In Focus
Data from Stocktwits shows that retail sentiment has held at ‘bullish’ on SPY, but sits at a cautious ‘neutral’ on QQQ.
Stocktwits
RVMD Stock Jumps Overnight: New Drug Heads To FDA After ‘Unprecedented’ 1-Year Survival Win In Pancreatic Cancer
The drugmaker reported Phase 3 pancreatic cancer trial results that pushed median survival beyond one year for the first time.
Stocktwits
Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report
Cancer centers race to access Revolution Medicines' pancreatic cancer drug after trial data showed survival doubled.read more...
Benzinga
Top Research Reports for Home Depot, TJX & Marvell Technology
HD, TJX and MRVL lead Zacks' top research picks as analysts highlight AI demand, retail resilience and Pro-focused growth strategies.
Zacks
$100 Invested In Revolution Medicines 5 Years Ago Would Be Worth This Much Today
read more...
Benzinga
Revolution Medicines (RVMD) Receives FDA's Safe to Proceed Letter for Daraxonrasib
Revolution Medicines (RVMD) Receives FDA's Safe to Proceed Letter for Daraxonrasib...
Yahoo! Finance: News
RVMD Reports Wider-Than-Expected Loss in Q1, Raises '26 Expense View
Revolution Medicines posts a wider Q1 loss and raises its 2026 expense outlook as R&D and commercial prep costs climb.